Developer docs
API playgroundTry for free, no card

Search company profiles

Unimax

Full company profile

uuid003e58d

Namestring
Unimax
Legal namestring
Unimax Chemicals Pvt Ltd
Websiteurl
unimax.co.in
Company typeenum
Private
Founded yearint
1985
Descriptiontext

Unimax is a privately held Indian pharmaceutical manufacturer operating through two core subsidiaries: Unimax Chemicals Pvt Ltd (UCPL), focused on macrolide antibiotic APIs including erythromycin salts, azithromycin variants, clarithromycin, and roxithromycin along with related intermediates; and Unimax Laboratories Pvt Ltd (ULPL), a dedicated facility for glucocorticosteroid APIs including dexamethasone and betamethasone compounds. Founded in 1985 (originally as Nirav Fine Chemicals) with the current entity established in 1990, the company operates three cGMP-compliant manufacturing facilities in Tarapur, India with combined annual production capacity of 300 metric tons, including a newly inaugurated EUGMP and USFDA-compliant block in 2023. The company's technology base spans complex organic chemistry (chiral chemistry, Beckmann's re-arrangement, Grignard reactions, Friedel-Crafts), green chemistry process development, and ISO 8 clean-room finishing capabilities for crystallization, drying, milling, blending, and micronization.

Unimax generates revenue through three streams: (1) sale of generic APIs and intermediates to API/formulation manufacturers globally (described as a one-time license/transactional model), (2) supply of macrolide intermediates (Erythromycin Oxime Base, Imino Ether) to API manufacturers, and (3) custom synthesis and contract manufacturing services for global pharmaceutical innovators and Big Pharma companies. Its go-to-market is direct B2B enterprise sales complemented by event-driven lead generation at industry exhibitions such as CPHI Barcelona 2023. Pricing is custom-quoted based on product specifications, volume, regulatory documentation, and destination-country registration requirements. The company holds WHO GMP, EU Written Confirmation, CEP Registration Number 2023-189 for Erythromycin Base, and FDA Maharashtra/DGDA certifications, serving customers in over 50 countries across Asia, Europe, Middle East, Asia Pacific, and Latin America. Leadership is family-controlled, with 100+ employees across the group and a development pipeline expanding into antiepileptics, antiplatelets, NSAIDs, and antidiabetics beyond the historical antibiotic/corticosteroid core.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMumbai, India
HQ citystring
Mumbai
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical API manufacturing, generic active pharmaceutical ingredients, macrolide antibiotic APIs, glucocorticoid steroid APIs, contract pharmaceutical manufacturing
Industry1 code
PRIMARYHLAIABAG
Generic APIs & Intermediates (Active Ingredients)
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Miscellaneous Chemical Products2890
Product category
Pharmaceutical API Manufacturing
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Generic API Sales
TypeOne Time License
Description

Sale of manufactured generic Active Pharmaceutical Ingredients including Erythromycin-based antibiotics, Azithromycin, Clarithromycin, and Glucocorticosteroids to API and formulation companies globally

unimax.co.in
2Pharmaceutical Intermediates
TypeOne Time License
Description

Supply of pharmaceutical intermediates including Erythromycin Oxime Base, Imino Ether, and other macrolide intermediates to API manufacturers

unimax.co.in
3Contract Manufacturing Services
TypeProfessional Services
Description

Custom synthesis and contract manufacturing services for global innovator companies and pharmaceutical majors. Development and optimization of processes for APIs and intermediates

unimax.co.in
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1UCPL
Description

Product division offering APIs, intermediates, and products under development including Erythromycin-based products, Azithromycin, Clarithromycin, and others

unimax.co.in
+1 more record
Core offering1 text field

Unimax is a research-driven Indian pharmaceutical manufacturer that produces and globally supplies generic Active Pharmaceutical Ingredients (APIs) and pharmaceutical intermediates — specializing in macrolide antibiotics (Erythromycin, Azithromycin, Clarithromycin, Roxithromycin) and glucocorticoid steroids (Dexamethasone, Betamethasone, Prednisolone, Mometasone) — and offers custom synthesis and contract manufacturing services to global innovator and Big Pharma companies from three cGMP-compliant manufacturing facilities with a combined 300MT annual capacity.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Over 26 generic API products offered globally
+3 more records
Product overview1 text field

Unimax is a pharmaceutical company operating through two main business units: UCPL (Unimax Chemicals Pvt Ltd) and ULPL (Unimax Laboratories Pvt Ltd). UCPL specializes in macrolide antibiotic APIs including erythromycin-based products, azithromycin variants, clarithromycin, and roxithromycin, along with related intermediates for these antibiotics. ULPL operates as a dedicated glucocorticoid corticosteroid manufacturing facility producing APIs like dexamethasone, betamethasone, and related steroid compounds. The company also offers contract manufacturing services for global pharmaceutical innovators. Unimax provides over 26 generic API products globally and develops new molecules across therapeutic categories including antifungals, antivirals, antihypertensives, antidiabetics, and NSAIDs. Products are available in multiple pharmacopoeia standards (IP/BP/EP/USP/JP) with WHO GMP and EU Written Confirmation certifications.

Product and service3 records
1Generic Active Pharmaceutical Ingredients (APIs)
CategoryGeneric Pharmaceutical APIs
Description

Over 26 generic Active Pharmaceutical Ingredients manufactured and supplied globally, comprising macrolide antibiotics (Erythromycin Base and salts such as Stearate, Estolate, Ethyl Succinate, Propionate, Phosphate, Lactobionate, 11-12 cyclic carbonate; Azithromycin Dihydrate, Anhydrous/Base, Monohydrate, taste-masked powder, premix for suspension; Clarithromycin Powder; Roxithromycin) and glucocorticoid corticosteroids (Dexamethasone Sodium Phosphate, Betamethasone Sodium Phosphate, Prednisolone Sodium Phosphate, Mometasone Furoate, Betamethasone Dipropionate, Beclomethasone Dipropionate, Betamethasone 17 Valerate, Clobetasole 17 Propionate, Triamcinolone Acetonide, Diflucortolone Valerate). Available in IP/BP/EP/USP/JP pharmacopoeia standards with WHO-GMP and EU Written Confirmation certifications. Targeted at global API manufacturers, formulation companies, big pharma, and multinational companies.

2Pharmaceutical Intermediates
CategoryPharmaceutical Intermediates
Description

Pharmaceutical intermediates supplied from a WHO-GMP approved plant, including macrolide intermediates such as Erythromycin Oxime Base, Imino Ether, Des Azithromycin/Aza Amine, 6-O-Methyl-2',4''-bis-O-(trimethylsilyl)erythromycin 9-[O-(1-ethoxy-1-methylethyl)oxime], and Silylated Erythromycin Oxime Ketal, used in the production of Azithromycin and Clarithromycin. Targeted at API manufacturing companies seeking quality intermediates and backward-integration support.

3Contract Manufacturing Services
CategoryContract Manufacturing Services
Description

Custom synthesis and contract manufacturing services for APIs and intermediates provided to global pharmaceutical innovators and big pharma companies. Capabilities include handling high energetic reactions, development and optimization of processes for APIs and intermediates, and development of non-infringing processes for strategic patent-constrained products. Targeted at global innovator companies and pharmaceutical majors needing a cGMP-compliant manufacturing partner with flexible capacity from gram-scale to MT.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Global Pharmaceutical Innovators
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Unimax provides contract manufacturing services for APIs and intermediates to global pharmaceutical innovators and big pharma companies. Capabilities include handling high energetic reactions and developing optimized non-infringing processes for strategic partnership collaborations.

unimax.co.in
Recent move11 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global generic API division of Teva Pharmaceutical, one of the world's largest producers of steroid and macrolide APIs. A broader incumbent competing with Unimax across multiple product categories and regulated geographies.

TypeDirect peer
Description

Indian API and formulation manufacturer with direct overlap in macrolide antibiotics and corticosteroids. Highly comparable to Unimax in scale, product mix (API + intermediates + formulations), and customer base of generic formulation companies.

TypeDirect peer
Description

Indian API and intermediates manufacturer serving pharma and agrochemical customers with active presence in macrolide intermediates. Directly comparable to Unimax's UCPL business in intermediates supply and custom synthesis capabilities.

TypeDirect peer
Description

Dutch-headquartered global leader in generic beta-lactam and macrolide antibiotic APIs. Highly comparable to Unimax because it competes directly in Erythromycin, Azithromycin, and Clarithromycin APIs and serves the same global formulation customer base.

TypeBroad incumbent
Description

One of India's largest API manufacturers with a broad generic API and custom synthesis portfolio. Comparable to Unimax in offering complex chemistry contract manufacturing and serving Big Pharma customers, but at significantly greater scale.

TypeDirect peer
Description

Indian-headquartered contract API manufacturer with global CRAMS operations. Comparable to Unimax because it competes in contract manufacturing and custom synthesis for innovator pharma, with overlapping complex chemistry capabilities.

7Sandoz (Novartis)
TypeBroad incumbent
Description

Global leader in generic APIs and finished dosages with vertical integration into API manufacturing. Competes with Unimax as a buyer-side anchor customer in some products and a competing supplier in others, particularly in antibiotics and corticosteroids.

TypeDirect peer
Description

Indian API and finished dosage manufacturer with a portfolio that includes select antibiotics and is expanding into corticosteroids. Comparable to Unimax as a mid-sized Indian API player targeting global formulation customers with backward-integrated manufacturing.

TypeDirect peer
Description

Indian API manufacturer focused on steroids, hormones, and complex generics. A close peer to Unimax's ULPL business unit because both compete in corticosteroid APIs (Dexamethasone, Betamethasone, Prednisolone) for global formulation customers.

TypeBroad incumbent
Description

Large vertically integrated Indian generic API and finished dosage manufacturer with a broad macrolide and steroid portfolio. A relevant peer because it competes head-to-head with Unimax in the same generic API categories while also operating formulation businesses that pull through API demand.

Market position
Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Unimax

Pharmaceutical API Manufacturingunimax.co.in

What Unimax does

Unimax is a privately held Indian pharmaceutical manufacturer operating through two core subsidiaries: Unimax Chemicals Pvt Ltd (UCPL), focused on macrolide antibiotic APIs including erythromycin salts, azithromycin variants, clarithromycin, and roxithromycin along with related intermediates; and Unimax Laboratories Pvt Ltd (ULPL), a dedicated facility for glucocorticosteroid APIs including dexamethasone and betamethasone compounds. Founded in 1985 (originally as Nirav Fine Chemicals) with the current entity established in 1990, the company operates three cGMP-compliant manufacturing facilities in Tarapur, India with combined annual production capacity of 300 metric tons, including a newly inaugurated EUGMP and USFDA-compliant block in 2023. The company's technology base spans complex organic chemistry (chiral chemistry, Beckmann's re-arrangement, Grignard reactions, Friedel-Crafts), green chemistry process development, and ISO 8 clean-room finishing capabilities for crystallization, drying, milling, blending, and micronization.

Unimax generates revenue through three streams: (1) sale of generic APIs and intermediates to API/formulation manufacturers globally (described as a one-time license/transactional model), (2) supply of macrolide intermediates (Erythromycin Oxime Base, Imino Ether) to API manufacturers, and (3) custom synthesis and contract manufacturing services for global pharmaceutical innovators and Big Pharma companies. Its go-to-market is direct B2B enterprise sales complemented by event-driven lead generation at industry exhibitions such as CPHI Barcelona 2023. Pricing is custom-quoted based on product specifications, volume, regulatory documentation, and destination-country registration requirements. The company holds WHO GMP, EU Written Confirmation, CEP Registration Number 2023-189 for Erythromycin Base, and FDA Maharashtra/DGDA certifications, serving customers in over 50 countries across Asia, Europe, Middle East, Asia Pacific, and Latin America. Leadership is family-controlled, with 100+ employees across the group and a development pipeline expanding into antiepileptics, antiplatelets, NSAIDs, and antidiabetics beyond the historical antibiotic/corticosteroid core.

Unimax firmographics

Firmographics
Name
Unimax
Legal name
Unimax Chemicals Pvt Ltd
Website
https://unimax.co.in
Company type
Private
Founded year
1985
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Unimax industry classification

Industry
Product category
Pharmaceutical API Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing (3254)
SIC
Miscellaneous Chemical Products (2890)
akta.pro industry
PRIMARYHLAIABAG
Generic APIs & Intermediates (Active Ingredients)

Keywords

  • Pharmaceutical API manufacturing
  • Generic active pharmaceutical ingredients
  • Macrolide antibiotic APIs
  • Glucocorticoid steroid APIs
  • Contract pharmaceutical manufacturing

Where Unimax is headquartered

Location

Headquarters

HQ city
Mumbai
HQ country
India
HQ region
Asia

Offices4 records

Markets served

Unimax business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

  1. Generic API Sales: Sale of manufactured generic Active Pharmaceutical Ingredients including Erythromycin-based antibiotics, Azithromycin, Clarithromycin, and Glucocorticosteroids to API and formulation companies globally
  2. Pharmaceutical Intermediates: Supply of pharmaceutical intermediates including Erythromycin Oxime Base, Imino Ether, and other macrolide intermediates to API manufacturers
  3. Contract Manufacturing Services: Custom synthesis and contract manufacturing services for global innovator companies and pharmaceutical majors. Development and optimization of processes for APIs and intermediates

Go-to-market motion2 records

Distribution channels1 record

Marketing channels1 record

Unimax product offering

Product offering

Core offering

Unimax is a research-driven Indian pharmaceutical manufacturer that produces and globally supplies generic Active Pharmaceutical Ingredients (APIs) and pharmaceutical intermediates — specializing in macrolide antibiotics (Erythromycin, Azithromycin, Clarithromycin, Roxithromycin) and glucocorticoid steroids (Dexamethasone, Betamethasone, Prednisolone, Mometasone) — and offers custom synthesis and contract manufacturing services to global innovator and Big Pharma companies from three cGMP-compliant manufacturing facilities with a combined 300MT annual capacity.

Product overview

Unimax is a pharmaceutical company operating through two main business units: UCPL (Unimax Chemicals Pvt Ltd) and ULPL (Unimax Laboratories Pvt Ltd). UCPL specializes in macrolide antibiotic APIs including erythromycin-based products, azithromycin variants, clarithromycin, and roxithromycin, along with related intermediates for these antibiotics. ULPL operates as a dedicated glucocorticoid corticosteroid manufacturing facility producing APIs like dexamethasone, betamethasone, and related steroid compounds. The company also offers contract manufacturing services for global pharmaceutical innovators. Unimax provides over 26 generic API products globally and develops new molecules across therapeutic categories including antifungals, antivirals, antihypertensives, antidiabetics, and NSAIDs. Products are available in multiple pharmacopoeia standards (IP/BP/EP/USP/JP) with WHO GMP and EU Written Confirmation certifications.

Differentiator

Problem solved

Functional benefit

Brands

  • UCPL: Product division offering APIs, intermediates, and products under development including Erythromycin-based products, Azithromycin, Clarithromycin, and others
  • ULPL

Products and services

  • Generic Active Pharmaceutical Ingredients (APIs) Over 26 generic Active Pharmaceutical Ingredients manufactured and supplied globally, comprising macrolide antibiotics (Erythromycin Base and salts such as Stearate, Estolate, Ethyl Succinate, Propionate, Phosphate, Lactobionate, 11-12 cyclic carbonate; Azithromycin Dihydrate, Anhydrous/Base, Monohydrate, taste-masked powder, premix for suspension; Clarithromycin Powder; Roxithromycin) and glucocorticoid corticosteroids (Dexamethasone Sodium Phosphate, Betamethasone Sodium Phosphate, Prednisolone Sodium Phosphate, Mometasone Furoate, Betamethasone Dipropionate, Beclomethasone Dipropionate, Betamethasone 17 Valerate, Clobetasole 17 Propionate, Triamcinolone Acetonide, Diflucortolone Valerate). Available in IP/BP/EP/USP/JP pharmacopoeia standards with WHO-GMP and EU Written Confirmation certifications. Targeted at global API manufacturers, formulation companies, big pharma, and multinational companies.
  • Pharmaceutical Intermediates Pharmaceutical intermediates supplied from a WHO-GMP approved plant, including macrolide intermediates such as Erythromycin Oxime Base, Imino Ether, Des Azithromycin/Aza Amine, 6-O-Methyl-2',4''-bis-O-(trimethylsilyl)erythromycin 9-[O-(1-ethoxy-1-methylethyl)oxime], and Silylated Erythromycin Oxime Ketal, used in the production of Azithromycin and Clarithromycin. Targeted at API manufacturing companies seeking quality intermediates and backward-integration support.
  • Contract Manufacturing Services Custom synthesis and contract manufacturing services for APIs and intermediates provided to global pharmaceutical innovators and big pharma companies. Capabilities include handling high energetic reactions, development and optimization of processes for APIs and intermediates, and development of non-infringing processes for strategic patent-constrained products. Targeted at global innovator companies and pharmaceutical majors needing a cGMP-compliant manufacturing partner with flexible capacity from gram-scale to MT.

Quantifiable outcome

  • Over 26 generic API products offered globally
  • +3 more outcomes

Companies that use Unimax

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Unimax technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Unimax partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Global Pharmaceutical InnovatorscoreStrategic or Co-development PartnerUnimax provides contract manufacturing services for APIs and intermediates to global pharmaceutical innovators and big pharma companies. Capabilities include handling high energetic reactions and developing optimized non-infringing processes for strategic partnership collaborations.

Scale indicators8 records

Recent moves11 records

Expansion highlights5 records

Unimax competitors and assessment

Company assessment

Broad incumbents

  • Teva API: Global generic API division of Teva Pharmaceutical, one of the world's largest producers of steroid and macrolide APIs. A broader incumbent competing with Unimax across multiple product categories and regulated geographies.
  • Divi's Laboratories: One of India's largest API manufacturers with a broad generic API and custom synthesis portfolio. Comparable to Unimax in offering complex chemistry contract manufacturing and serving Big Pharma customers, but at significantly greater scale.
  • Sandoz (Novartis): Global leader in generic APIs and finished dosages with vertical integration into API manufacturing. Competes with Unimax as a buyer-side anchor customer in some products and a competing supplier in others, particularly in antibiotics and corticosteroids.
  • Aurobindo Pharma: Large vertically integrated Indian generic API and finished dosage manufacturer with a broad macrolide and steroid portfolio. A relevant peer because it competes head-to-head with Unimax in the same generic API categories while also operating formulation businesses that pull through API demand.

Direct peers

  • Ipca Laboratories: Indian API and formulation manufacturer with direct overlap in macrolide antibiotics and corticosteroids. Highly comparable to Unimax in scale, product mix (API + intermediates + formulations), and customer base of generic formulation companies.
  • Hikal Limited: Indian API and intermediates manufacturer serving pharma and agrochemical customers with active presence in macrolide intermediates. Directly comparable to Unimax's UCPL business in intermediates supply and custom synthesis capabilities.
  • Centrient Pharmaceuticals: Dutch-headquartered global leader in generic beta-lactam and macrolide antibiotic APIs. Highly comparable to Unimax because it competes directly in Erythromycin, Azithromycin, and Clarithromycin APIs and serves the same global formulation customer base.
  • Dishman Carbogen Amcis: Indian-headquartered contract API manufacturer with global CRAMS operations. Comparable to Unimax because it competes in contract manufacturing and custom synthesis for innovator pharma, with overlapping complex chemistry capabilities.
  • Granules India: Indian API and finished dosage manufacturer with a portfolio that includes select antibiotics and is expanding into corticosteroids. Comparable to Unimax as a mid-sized Indian API player targeting global formulation customers with backward-integrated manufacturing.
  • SMS Pharmaceuticals: Indian API manufacturer focused on steroids, hormones, and complex generics. A close peer to Unimax's ULPL business unit because both compete in corticosteroid APIs (Dexamethasone, Betamethasone, Prednisolone) for global formulation customers.

Market position

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Unimax compliance and trust

Trust signal

Compliance3 records

Unimax financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Unimax leadership team

Management profile

Number of profiles

Profiles7 records

Unimax subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Unimax funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Unimax M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Unimax

What does Unimax do?

Unimax is a research-driven Indian pharmaceutical manufacturer that produces and globally supplies generic Active Pharmaceutical Ingredients (APIs) and pharmaceutical intermediates — specializing in macrolide antibiotics (Erythromycin, Azithromycin, Clarithromycin, Roxithromycin) and glucocorticoid steroids (Dexamethasone, Betamethasone, Prednisolone, Mometasone) — and offers custom synthesis and contract manufacturing services to global innovator and Big Pharma companies from three cGMP-compliant manufacturing facilities with a combined 300MT annual capacity.

Is Unimax a public or private company?

Unimax is a private company. It is classified as family owned and is currently operating.

When was Unimax founded?

Unimax was founded in 1985. It employs 11 to 50 people.

Where is Unimax based?

Unimax is headquartered in Mumbai, India, in the Asia region.

How does Unimax make money?

Three revenue lines are on record. Generic API Sales are the primary driver. The others are pharmaceutical Intermediates and contract Manufacturing Services.

Who are Unimax's main competitors?

Broad incumbents on record are Teva API, Divi's Laboratories, Sandoz (Novartis) and Aurobindo Pharma. Direct peers are Ipca Laboratories, Hikal Limited, Centrient Pharmaceuticals, Dishman Carbogen Amcis, Granules India and SMS Pharmaceuticals.

Does Unimax have an API?

No public API is recorded for Unimax.

What industry is Unimax in?

Unimax's product category is Pharmaceutical API Manufacturing. Its primary akta.pro industry code is HLAIABAG, Generic APIs & Intermediates (Active Ingredients). Its NAICS code is 3254 and its SIC code is 2890.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales